Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
Risitano AM, Marotta S, Ricci P, Marano L, Frieri C, Cacace F, Sica M, Kulasekararaj A, Calado RT, Scheinberg P, Notaro R, Peffault de Latour R.
Front Immunol. 2019 Jun 14;10:1157. doi: 10.3389/fimmu.2019.01157. eCollection 2019.
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.
Zeidan AM, Platzbecker U, Bewersdorf JP, Stahl M, Adès L, Borate U, Bowen D, Buckstein R, Brunner A, Carraway HE, Daver N, Díez-Campelo M, de Witte T, DeZern AE, Efficace F, Garcia-Manero G, Garcia JS, Germing U, Giagounidis A, Griffiths EA, Hasserjian RP, Hellström-Lindberg E, Iastrebner M, Komrokji R, Kulasekararaj AG, Malcovati L, Miyazaki Y, Odenike O, Santini V, Sanz G, Scheinberg P, Stauder R, van de Loosdrecht AA, Wei AH, Sekeres MA, Fenaux P.
Blood. 2023 Apr 27;141(17):2047-2061. doi: 10.1182/blood.2022018604.
Olverembatinib treatment in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Zhu Y, Huang J, Wang Y, Han Y, Xue S, Yang Y, Zhu Y, Cai W, Chen S.
Ann Hematol. 2024 Nov;103(11):4643-4648. doi: 10.1007/s00277-024-06027-w. Epub 2024 Oct 14.
Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial.
Yamazaki T, Gunderson AJ, Gilchrist M, Whiteford M, Kiely MX, Hayman A, O'Brien D, Ahmad R, Manchio JV, Fox N, McCarty K, Phillips M, Brosnan E, Vaccaro G, Li R, Simon M, Bernstein E, McCormick M, Yamasaki L, Wu Y, Drokin A, Carnahan T, To Y, Redmond WL, Lee B, Louie J, Hansen E, Solhjem MC, Cramer J, Urba WJ, Gough MJ, Crittenden MR, Young KH.
Lancet Oncol. 2022 Sep;23(9):1189-1200. doi: 10.1016/S1470-2045(22)00446-6. Epub 2022 Aug 8.
Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis.
LeVee A, Wong M, Flores S, Ruel N, McArthur H, Waisman J, Mortimer J.
Oncologist. 2024 Jul 5;29(7):566-574. doi: 10.1093/oncolo/oyae064.
Mass spectrometry and proteomics in hematology.
Rolland DCM, Lim MS, Elenitoba-Johnson KSJ.
Semin Hematol. 2019 Jan;56(1):52-57. doi: 10.1053/j.seminhematol.2018.05.009. Epub 2018 May 29.
Mosaic chromosomal alterations in hematopoietic cells and clinical outcomes in patients with multiple myeloma.
Husby S, Tulstrup M, Harsløf M, Nielsen C, Haastrup E, Ebbesen LH, Klarskov Andersen M, Pertesi M, Brieghel C, Niemann CU, Nilsson B, Szabo AG, Andersen NF, Abildgaard N, Vangsted A, Grønbæk K.
Leukemia. 2024 Nov;38(11):2456-2465. doi: 10.1038/s41375-024-02396-3. Epub 2024 Sep 2.
Cardiac Response Dynamics in Newly Diagnosed Light-Chain Amyloidosis Patients With Early and High-Quality Hematologic Response.
Xu CY, Guan A, Zhang L, Tian Z, Zhou DB, Shen KN, Li J.
JACC Asia. 2024 Nov 26;5(1):74-84. doi: 10.1016/j.jacasi.2024.10.005. eCollection 2025 Jan.
Recent advances in T-cell immunotherapy for haematological malignancies.
Rouce RH, Sharma S, Huynh M, Heslop HE.
Br J Haematol. 2017 Mar;176(5):688-704. doi: 10.1111/bjh.14470. Epub 2016 Nov 29.
Practical monitoring of chronic myelogenous leukemia: when to change treatment.
Saglio G, Fava C.
J Natl Compr Canc Netw. 2012 Jan;10(1):121-9. doi: 10.6004/jnccn.2012.0011.
